Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score-Reference-Cited by-同舟云学术

Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score

Published:2022-10 Issue:4 Volume:163 Page:1104-1106.e3
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Kim Nicole J.,Vutien Philip,Berry Kristin,Ioannou George N.^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference9 articles.

1. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

2. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

3. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

4. Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents

5. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASL position paper on clinical follow-up after HCV cure;Journal of Hepatology;2024-08

2. Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices;Digestive Diseases and Sciences;2024-04-23

3. Hepatocellular Carcinoma in the Era of Direct Antiviral Agents Against Hepatitis C Virus;Current Hepatology Reports;2024-03-18

4. Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review;Liver Cancer;2024

5. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication;Alimentary Pharmacology & Therapeutics;2023-11-13